These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3934802)

  • 61. Studies of mouse polyoma virus infection. II. Virus stability.
    BRODSKY I; ROWE WP; HARTLEY JW; LANE WT
    J Exp Med; 1959 May; 109(5):439-47. PubMed ID: 13641568
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The effects of salts on virus inactivation by lyophilization and dry heat.
    Wickerhauser M; Williams C
    Vox Sang; 1987; 53(3):188-9. PubMed ID: 3686944
    [No Abstract]   [Full Text] [Related]  

  • 63. Factor 8 (AHF) concentration in pH 6.5 citrate-plasma.
    Morrison FS
    Blood; 1966 Sep; 28(3):479-82. PubMed ID: 5918473
    [No Abstract]   [Full Text] [Related]  

  • 64. Sindbis virus as a tool for quality control of viral inactivation of heated and chemically treated plasma-derived products.
    Espíndola OM; Belluci MS; Oliveira BC; Liberto MI; Cabral MC
    J Virol Methods; 2006 Jun; 134(1-2):171-5. PubMed ID: 16507321
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inactivation of viruses in blood with aluminum phthalocyanine derivatives.
    Horowitz B; Williams B; Rywkin S; Prince AM; Pascual D; Geacintov N; Valinsky J
    Transfusion; 1991 Feb; 31(2):102-8. PubMed ID: 1847558
    [TBL] [Abstract][Full Text] [Related]  

  • 67. "In vitro" and in animal model studies on a double virus-inactivated factor VIII concentrate.
    Arrighi S; Rossi R; Borri MG; Lesnikov V; Lesnikova M; Franco E; Divizia M; De Santis ME; Bucci E
    Thromb Haemost; 1995 Sep; 74(3):868-73. PubMed ID: 8571312
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The efficacy and safety of lyophilized cryoprecipitate in hemophilia A.
    Chuansumrit A; Isarangkura P; Chantanakajornfung A; Kuhathong K; Pintadit P; Jitpraphai C; Hathirat P; Nuchprayoon C
    J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S69-73. PubMed ID: 10730521
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Current safety of clotting factor concentrates.
    Epstein JS; Fricke WA
    Arch Pathol Lab Med; 1990 Mar; 114(3):335-40. PubMed ID: 2407224
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates.
    Berting A; Modrof J; Unger U; Gessner M; Klotz A; Poelsler G; Kreil TR
    Transfusion; 2008 Jun; 48(6):1220-6. PubMed ID: 18410254
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fish viruses stored in RNAlater can remain infectious and even be temporarily protected from inactivation by heat or by tissue homogenates.
    Pham PH; Sokeechand BSH; Garver KA; Jones G; Lumsden JS; Bols NC
    J Virol Methods; 2018 Mar; 253():31-37. PubMed ID: 29288073
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Virus inactivation of plasma-derived proteins by pasteurization in the presence of guanidine hydrochloride.
    Schlegel A; Immelmann A; Kempf C
    Transfusion; 2001 Mar; 41(3):382-9. PubMed ID: 11274595
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inactivation of viruses during a new manufacturing process of α2-macroglobulin from Cohn Fraction IV by dry-heat treatment.
    Huangfu C; Zhao X; Lv M; Jia J; Zhu F; Wang R; Ma Y; Zhang J
    Transfusion; 2016 Sep; 56(9):2274-7. PubMed ID: 27383449
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A pasteurized therapeutic plasma.
    Burnouf-Radosevich M; Burnouf T; Huart JJ
    Infusionsther Transfusionsmed; 1992 Apr; 19(2):91-4. PubMed ID: 1623326
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Research Advance on Preparation Technology and Application of Virus-inactivated Lyophilized Plasma---Review].
    Fan B; Zhu LG; Wang DQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1658-1661. PubMed ID: 34627457
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of Gamma Irradiation on the Osteoinductivity of Demineralized Dentin Matrix for Allografts: A Preliminary Study.
    Ku JK; Kim IH; Um IW; Kim BH; Yun PY
    J Funct Biomater; 2022 Jan; 13(1):. PubMed ID: 35225977
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Assessment of the viral safety of antivenoms fractionated from equine plasma.
    Burnouf T; Griffiths E; Padilla A; Seddik S; Stephano MA; Gutiérrez JM
    Biologicals; 2004 Sep; 32(3):115-28. PubMed ID: 15536042
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The development of virus-free labile blood derivatives--a review.
    Prince AM; Horowitz B; Horowitz MS; Zang E
    Eur J Epidemiol; 1987 Jun; 3(2):103-18. PubMed ID: 3301391
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Blood transfusion and hepatitis: still a threat?
    Reesink HW; van der Poel CL
    Blut; 1989 Jan; 58(1):1-6. PubMed ID: 2644993
    [TBL] [Abstract][Full Text] [Related]  

  • 80. HIV transmission to patients with hemophilia by heat-treated, donor-screened factor concentrate.
    Remis RS; O'Shaughnessy MV; Tsoukas C; Growe GH; Schechter MT; Palmer RW; Lawrence DN
    CMAJ; 1990 Jun; 142(11):1247-54. PubMed ID: 2111726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.